127 related articles for article (PubMed ID: 36244542)
1. IKBIP, a novel glioblastoma biomarker, maintains abnormal proliferation of tumor cells by inhibiting the ubiquitination and degradation of CDK4.
Li K; Huang G; Wang Z; Yang R; Zhang W; Ni B; Guan J; Yi G; Li Z; Zhu Q; Peng Q; Yang L; Qi L; Liu Y
Biochim Biophys Acta Mol Basis Dis; 2023 Jan; 1869(1):166571. PubMed ID: 36244542
[TBL] [Abstract][Full Text] [Related]
2. IKBIP might be a potential prognostic biomarker for glioblastoma multiforme.
Chen H; Liang B; Luo X; Zhang W; Song X; Lan H; Yue Q; Xie J; Zhang M
Int Immunopharmacol; 2023 May; 118():110030. PubMed ID: 36989893
[TBL] [Abstract][Full Text] [Related]
3. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
[TBL] [Abstract][Full Text] [Related]
4. CDK4, CDK6, cyclin D1, p16(INK4a) and EGFR expression in glioblastoma with a primitive neuronal component.
Xu G; Li JY
J Neurooncol; 2018 Feb; 136(3):445-452. PubMed ID: 29150788
[TBL] [Abstract][Full Text] [Related]
5. Suppression of tumorigenicity by microRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme.
Qiu S; Huang D; Yin D; Li F; Li X; Kung HF; Peng Y
Biochim Biophys Acta; 2013 Oct; 1832(10):1697-707. PubMed ID: 23707559
[TBL] [Abstract][Full Text] [Related]
6. Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma.
Olmez I; Zhang Y; Manigat L; Benamar M; Brenneman B; Nakano I; Godlewski J; Bronisz A; Lee J; Abbas T; Abounader R; Purow B
Cancer Res; 2018 Aug; 78(15):4360-4369. PubMed ID: 29844123
[TBL] [Abstract][Full Text] [Related]
7. DMC-siERCC2 hybrid nanoparticle enhances TRAIL sensitivity by inducing cell cycle arrest for glioblastoma treatment.
Song M; Wang T; Liu T; Lei T; Teng X; Peng Q; Zhu Q; Chen F; Zhao G; Li K; Qi L
Biomed Pharmacother; 2024 May; 174():116470. PubMed ID: 38565061
[TBL] [Abstract][Full Text] [Related]
8. A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.
Yin L; Li H; Liu W; Yao Z; Cheng Z; Zhang H; Zou H
Eur J Med Chem; 2018 Jan; 144():1-28. PubMed ID: 29247857
[TBL] [Abstract][Full Text] [Related]
9. ZWINT: A potential therapeutic biomarker in patients with glioblastoma correlates with cell proliferation and invasion.
Yang L; Han N; Zhang X; Zhou Y; Chen R; Zhang M
Oncol Rep; 2020 Jun; 43(6):1831-1844. PubMed ID: 32323832
[TBL] [Abstract][Full Text] [Related]
10.
Yang Y; Wang J; Xu S; Lv W; Shi F; Shan A
Transl Neurosci; 2021 Jan; 12(1):9-19. PubMed ID: 33552590
[TBL] [Abstract][Full Text] [Related]
11. A Potential Anti-Glioblastoma Compound LH20 Induces Apoptosis and Arrest of Human Glioblastoma Cells via CDK4/6 Inhibition.
Wang Y; Li Y; Liu D; Zheng D; Li X; Li C; Huang C; Wang Y; Wang X; Li Q; Xu J
Molecules; 2023 Jun; 28(13):. PubMed ID: 37446710
[TBL] [Abstract][Full Text] [Related]
12. Ara-c induces cell cycle G1/S arrest by inducing upregulation of the INK4 family gene or directly inhibiting the formation of the cell cycle-dependent complex CDK4/cyclin D1.
Sun F; Li N; Tong X; Zeng J; He S; Gai T; Bai Y; Liu L; Lu K; Shen J; Han M; Lu C; Dai F
Cell Cycle; 2019 Sep; 18(18):2293-2306. PubMed ID: 31322047
[TBL] [Abstract][Full Text] [Related]
13. Cytoplasmic cyclin D1 regulates glioblastoma dissemination.
Cemeli T; Guasch-Vallés M; Nàger M; Felip I; Cambray S; Santacana M; Gatius S; Pedraza N; Dolcet X; Ferrezuelo F; Schuhmacher AJ; Herreros J; Garí E
J Pathol; 2019 Aug; 248(4):501-513. PubMed ID: 30957234
[TBL] [Abstract][Full Text] [Related]
14. miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway.
Liu Q; Guan Y; Li Z; Wang Y; Liu Y; Cui R; Wang Y
J Exp Clin Cancer Res; 2019 Aug; 38(1):358. PubMed ID: 31419987
[TBL] [Abstract][Full Text] [Related]
15. Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.
Bronner SM; Merrick KA; Murray J; Salphati L; Moffat JG; Pang J; Sneeringer CJ; Dompe N; Cyr P; Purkey H; Boenig GL; Li J; Kolesnikov A; Larouche-Gauthier R; Lai KW; Shen X; Aubert-Nicol S; Chen YC; Cheong J; Crawford JJ; Hafner M; Haghshenas P; Jakalian A; Leclerc JP; Lim NK; O'Brien T; Plise EG; Shalan H; Sturino C; Wai J; Xiao Y; Yin J; Zhao L; Gould S; Olivero A; Heffron TP
Bioorg Med Chem Lett; 2019 Aug; 29(16):2294-2301. PubMed ID: 31307887
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of RND3/RhoE in glioblastoma patients promotes tumorigenesis through augmentation of notch transcriptional complex activity.
Liu B; Lin X; Yang X; Dong H; Yue X; Andrade KC; Guo Z; Yang J; Wu L; Zhu X; Zhang S; Tian D; Wang J; Cai Q; Chen Q; Mao S; Chen Q; Chang J
Cancer Med; 2015 Sep; 4(9):1404-16. PubMed ID: 26108681
[TBL] [Abstract][Full Text] [Related]
17. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.
Wiedemeyer WR; Dunn IF; Quayle SN; Zhang J; Chheda MG; Dunn GP; Zhuang L; Rosenbluh J; Chen S; Xiao Y; Shapiro GI; Hahn WC; Chin L
Proc Natl Acad Sci U S A; 2010 Jun; 107(25):11501-6. PubMed ID: 20534551
[TBL] [Abstract][Full Text] [Related]
18. Direct inhibition of retinoblastoma phosphorylation by nimbolide causes cell-cycle arrest and suppresses glioblastoma growth.
Karkare S; Chhipa RR; Anderson J; Liu X; Henry H; Gasilina A; Nassar N; Ghosh J; Clark JP; Kumar A; Pauletti GM; Ghosh PK; Dasgupta B
Clin Cancer Res; 2014 Jan; 20(1):199-212. PubMed ID: 24170547
[TBL] [Abstract][Full Text] [Related]
19. MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma.
Jarboe JS; Anderson JC; Duarte CW; Mehta T; Nowsheen S; Hicks PH; Whitley AC; Rohrbach TD; McCubrey RO; Chiu S; Burleson TM; Bonner JA; Gillespie GY; Yang ES; Willey CD
Clin Cancer Res; 2012 Jun; 18(11):3030-41. PubMed ID: 22619307
[TBL] [Abstract][Full Text] [Related]
20. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
